Estimating the cost-effectiveness of one-time screening and treatment for hepatitis C in Korea

Do Young Kim, Kwang Hyub Han, Byungyool Jun, Tae Hyun Kim, Sohee Park, Thomas Ward, Samantha Webster, Phil McEwan

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


Background and Aims: This study aims to investigate the cost-effectiveness of a one-time hepatitis C virus (HCV) screening and treatment program in South Korea where hepatitis B virus (HBV) prevails, in people aged 40-70, compared to current practice (no screening). Methods: A published Markov model was used in conjunction with a screening and treatment decision tree to model patient cohorts, aged 40-49, 50-59 and 60-69 years, distributed across chronic hepatitis C (CHC) and compensated cirrhosis (CC) health states (82.5% and 17.5%, respectively). Based on a published seroepidemiology study, HCV prevalence was estimated at 0.60%, 0.80% and 1.53%, respectively. An estimated 71.7% of the population was screened. Post-diagnosis, 39.4% of patients were treated with a newly available all-oral direct-acting antiviral (DAA) regimen over 5 years. Published rates of sustained virologic response, disease management costs, transition rates and utilities were utilised. Results: Screening resulted in the identification of 43,635 previously undiagnosed patients across all cohorts. One-time HCV screening and treatment was estimated to be cost-effective across all cohorts; predicted incremental cost-effectiveness ratios ranged from $5,714 to $8,889 per quality-adjusted life year gained. Incremental costs associated with screening, treatment and disease management ranged from $156.47 to $181.85 million USD; lifetime costs-offsets associated with the avoidance of end stage liver disease complications ranged from $51.47 to $57.48 million USD. Conclusions: One-time HCV screening and treatment in South Korean people aged 40-70 is likely to be highly cost-effective compared to the current practice of no screening.

Original languageEnglish
Article number0167770
JournalPloS one
Issue number1
Publication statusPublished - 2017 Jan

Bibliographical note

Publisher Copyright:
© 2017 Kim et al.This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, andreproduction in any medium, provided the originalauthor and source are credited.

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'Estimating the cost-effectiveness of one-time screening and treatment for hepatitis C in Korea'. Together they form a unique fingerprint.

Cite this